Resilient Pharmaceuticals

Resilient Pharmaceuticals is the current public name SCM is using for the commercial MDMA/PTSD company formerly known as Lykos Therapeutics and, before that, MAPS Public Benefit Corporation. The company remains tied to the same regulatory story: the midomafetamine / MDMA-assisted therapy application for PTSD that FDA declined to approve in 2024.

Because FDA documents, ClinicalTrials.gov records, older company pages, and current reporting do not all use the same name, this page treats Resilient, Lykos, and MAPS PBC as a connected naming trail rather than separate companies for editorial purposes.

Source status on the rename

The cleanest public source support is not a Resilient press release. It is a combination of official and near-primary records: a Canadian Intellectual Property Office trademark record shows a name-change recordal from Lykos Therapeutics, Inc. to Resilient Pharmaceuticals, Inc.; MAPS describes Resilient as formerly Lykos Therapeutics; and Helena, an investor/project page, describes Resilient as formerly Lykos / MAPS PBC.

Timing of the name switch

The cleanest hard date is July 28, 2025: the CIPO trademark record lists that as the “date of change” for the name-change recordal from Lykos Therapeutics, Inc. to Resilient Pharmaceuticals, Inc. Public sector reporting appears to have followed later, with Psychedelic Alpha reporting the rebrand on August 28, 2025. SCM should keep those separate: July 28 is the recordal/legal marker in the checked source trail; late August is the public-reporting marker.

The caveat is important: the legacy Lykos site still appears live, and the checked ClinicalTrials.gov records for the main MDMA/PTSD studies still list Lykos Therapeutics as sponsor. Those records appear to preserve the historical sponsor name rather than reflecting the later rename.

Regulatory position

In June 2024, the FDA's Psychopharmacologic Drugs Advisory Committee reviewed NDA 215455 for midomafetamine capsules under the Lykos name. FDA later issued a Complete Response Letter rather than approving the drug, leaving the program in a redesign-and-rebuild position rather than a launch position.

The rename does not change that regulatory state. It is a company-map and source-trail update, not evidence of FDA approval, not evidence of a new trial result, and not evidence of any FDA CNPV voucher status.

Trial footprint

The core public trial record includes the completed multi-site Phase 3 PTSD studies MAPP1 (NCT03537014) and MAPP2 (NCT04077437), plus the open-label extension study MAPPUSX (NCT04714359). At the time checked for this update, those registry records still list the lead sponsor as Lykos Therapeutics.

Naming convention

SCM should use “Resilient Pharmaceuticals, formerly Lykos Therapeutics” on first reference for current company context. Use “Lykos Therapeutics” when describing FDA, advisory-committee, or trial-registry documents that used that name at the time.

What to watch

The central questions remain whether Resilient can define a credible new Phase 3 path, how FDA concerns about evidence and oversight get addressed, and whether the company can convert the pioneering MDMA/PTSD program into an approval-grade submission. Until then, the company remains important less as a commercial winner and more as the sector's clearest regulatory stress test.